Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
AZ to Commercialize Kyowa Kirin’s COPD Drug in Japan
Kyowa Hakko Kirin said on October 28 that AstraZeneca has exercised its exclusive option to commercialize the asthma/chronic obstructive pulmonary disease (COPD) treatment benralizumab in Japan - an IL-5 inhibitor originated by Kyowa Kirin. In July last year, the two…
To read the full story
Related Article
- AstraZeneca Grabs All Global Fasenra Rights in Expanded Pact with Kyowa Kirin
March 26, 2019
- Benralizumab Demonstrates Favorable Results in Subgroup Analysis of Japanese Bronchial Asthma Patients: AZ
April 24, 2017
- AZ Gets Asian Rights to Kyowa Kirin’s Benralizumab
March 27, 2017
- Kyowa Kirin Grants AZ Option Rights to Commercialization of Benralizumab in Japan
July 17, 2015
BUSINESS
- MSD Urges Swift Rollout of Routine HPV Vaccination for Males in Japan
July 29, 2026
- Takeda Files Entyvio IV for Pediatric Use, New Adult Dosing in Japan
July 29, 2026
- Japan OTC Market Falls for 4th Straight Month in June: Intage
July 29, 2026
- J-TEC, OSferionBiomaterials Join Forces to Expand Knee OA Business
July 29, 2026
- FunPep Allergy Vaccine Misses Exploratory Efficacy Goals in PI
July 29, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…